The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
doesn't exclusivity both ways imply that Medusa couldn't sell other 'competitors' tests? That would certainly be my understanding anyway. Now whether an antibody test can be said to be a competitor test is another question but given the links between the two companies one would have thought that the deal ought to have been struck in the way that I am suggesting. If indeed they are marketing two tests!
What you say may well be the case RedReversion.
The RNS of 20 May talks of an exclusive distribution agreement for direct to customer sales of a saliva based rapid test. I have no doubt that exclusivity will work both ways and the lawyers will have sorted it.
Of course there is nothing to stop Medusa selling other tests for AVCT or indeed other clients (at least as far as we know).
What they must not do and it would be actionable if they did would be to confuse any of avct's tests with anyone elses.
Someone it appears made a bit of a booboo (see what I did there) this afternoon.
These things happen.
It will increase the anxiety levels of Alwayswinning and give the rest of us a bit of a giggle (and an excuse for lots more speculation as if we needed an excuse)
Having calmed down a bit, it is clear to me now that Medusa have two tests for sale. The header graphic text makes this clear:
"Partnering with Rapid Saliva Test manufacturers to bring a total solution to rebuilding confidence..."
Notice the plural on manufacturers. It is also easier to see on the desktop (as opposed to the phone) that the two things are each a different test as they are shown side by side. One is Avacta, the other is 'Medusa 19'.
You can only imagine than the 'Medusa 19' test must be an antibody test. This is why Avacta have allowed it to be sold alongside their Antigen test. The two are complimentary. If you add in the Saturn Pass app to these two tests you have an impressive set of tools at your disposal for addressing the virus.
This is a positive for Avacta. The test stands on it's own but also works well in tandem with an antibody test. Can only result in more sales. Makes Medusa19 a one-stop-shop. Every marketeers dream.
I wrote it Toaster. You know me...
There are errors and typo’s which suggest it was posted in error. I take your point about it being a different test though!
But its not a rival test if its an antibody test Jimmy......
Scarratwho- you have got completely mixed up chap. This is nothing to do with Avacta and you are just somewhat bizarrely hoping it's some kind of web design error and not a rival test.
Take your head out of the sand and process all the information that is in front of you. NEW test out of Spain being manufactured by Medusa. No typos or web design errors, just a different kit.
My, you’re a delightful chap. :)
Thanks for your input. Though you’re rather missing the point.
Medusa 19 Life Sciences Ltd is an active company incorporated on 23 July 2020 with the registered office located in London, Greater London. Medusa 19 Life Sciences Ltd has been running for 22 days. There is currently 1 active director according to the latest confirmation statement submitted on 23rd July 2020.
Website still looks ****e on mobile but definately two tests and definately written in Indian English, so I'd say it's real
No indication of when the antibody test will be available, so is it ahead of ours? Even if not strictly comparable.
Why do people just copy and paste stuff like this that everyone can read / has read? They do it with RNS’s too.. what’s the point?
https://medusa19.com/
Medusa 19 are working with their partner, Medusa 19 Life Sciences, to exclusively bring to market the best in class saliva lateral flow test for early indication of SARS-CoV-2 proteins and highly accurate in identifying the virus in asymptomatic patients.
The Rapid Saliva Protein Test (RSPT) is a simple, non-invasive, on the spot test indicating infection from SARS-CoV-2, the virus underlying COVID-19.
It is a lateral flow test requiring a simple saliva sample, a comfortable and non-invasive collection process, providing rapid results within 10 minutes.
Comparable results with a PCR test for asymptomatic patients but without significant discomfort from throat and nasal swab and considerable delay in results.
94% sensitivity, 95% specificity and 95% accurate
Ahem,
Chengdo
Message from granny. She says she is a wonderful egg sucker. Apparantly she used to practice all the time on my grandad's b alls.
Thanks anyway. lol
Yes why sell one test when you can get double the sales revenue from two? Do you want the ‘Have I got it test.’ or the ‘Have I had it test’? Or both?
I didn’t say it matched, that paper was using a blood sample. The test on that ropey website suggested saliva, but I can’t find that test on t’internet.
My reading of this, is Medusa19 are going to be suppliers of multiple types of tests...
Whether or not it’s good news for Avacta, will now depending on quality& price versus other products Medusa supply.
If we find ourselves too expensive or lower on quality than the others, then it’s BAD news... as they are our only route to the consumer market.
The opposite is also true though.
DaDooRonRon - or perhaps Medusa will be selling more than one Avacta test but under different brand names/packaging. There may be options available depending on what mix of Sensitivity / Specificity you prefer ????
Please remember avacta is not an antibody test, so it doesn’t matter how far ahead this separate test is.
scarratwho- what are you going on about no offense but did you even read the page ?
This is a separate test, nothing to do with Avacta. An antibody test coming out of Spain I believe.
So there you have it. There are now two rapid tests and one is further ahead than Avacta's by the looks of it
I think it’s fair to say that I’ve been talking rubbish and there are two tests, our one, and an antibody test that medusa are developing separately.
If it's some other test then shafted or a cute move ???
I would also say, that I have worked with loads of terrible, sloppy, careless developers, so it’s just as likely to be their regular person who has messed up!
Still, looks and feels genuine to me though.
If the UK government is planning to take the lion’s share of BBI’s production capacity perhaps Medusa will have to offer other tests as well as Avacta?
Why would it ‘match up’? It’s not Avacta!